|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Fecal microbiota transplantation as novel therapy in gastroenterology:A systematic review显示文摘AIM:To study the clinical efficacy and safety of Fecal microbiota transplantation(FMT).We systematically reviewed FMT used as clinical therapy.METHODS:We searched MEDLINE,EMBASE,the Cochrane Library and Conference proceedings from inception to July,2013.Treatment effect of FMT was calculated as the percentage of patients who achieved clinical improvement per patient category,on an intention-to-treat basis.RESULTS:We included 45 studies;34 on Clostridium difficile-infection(CDI),7 on inflammatory bowel disease,1 on metabolic syndrome,1 on constipation,1 on pouchitis and 1 on irritable bowel syndrome(IBS).In CDI 90% resolution of diarrhea in 33 case series(n = 867) was reported,and 94% resolution of diarrhea after repeated FMT in a randomized controlled trial(RCT)(n = 16).In ulcerative colitis(UC) remission rates of 0% to 68% were found(n = 106).In Crohn's disease(CD)(n = 6),no benefit was observed.In IBS,70% improvement of symptoms was found(n = 13).100% Reversal of symptoms was observed in constipation(n = 3).In pouchitis,none of the patients(n = 8) achieved remission.One RCT showed significant improvement of insulin sensitivity in metabolic syndrome(n = 10).Serious adverse events were rare.CONCLUSION:FMT is highly effective in CDI,and holds promise in UC.As for CD,chronic constipation,pouchitis and IBS data are too limited to draw conclusions.FMT increases insulin sensitivity in metabolic syndrome. | Noortje G Rossen John K Mac Donald Elisabeth M de Vries Geert R D'Haens Willem M de Vos Erwin G Zoetendal Cyriel Y Ponsioen | 2015 | World Journal of Gastroenterology2015，21，17： | 41 |
| 2 | 帕博利珠单抗单用或与放疗联用治疗转移性非小细胞肺癌:两个随机试验的汇总分析显示文摘背景放疗可以提高整个机体对免疫治疗的应答。在Ⅱ期PEMBRO-RT研究和Ⅰ/Ⅱ期MDACC研究中,患有转移性非小细胞肺癌(NSCLC)的患者被随机分配入组,接受免疫治疗(帕博利珠单抗)+放疗联合疗法,或免疫治疗单一疗法。当上述2个研究单独分析时,联合疗法组显示出潜在获益。由于每个研究的样本量较小,缓解率和结局并未显示出统计学意义,然而却有显著的临床获益。因此,本研究进行汇总分析,来判断放疗是否会改善转移性NSCLC患者的免疫治疗应答。方法PEMBRO-RT和MDACC研究纳入标准:患者年龄≥18岁,患有转移性NSCLC,且有≥1处未经放疗照射的病灶,以便进行射野外应答监测。PEMBRO-RT研究纳入曾接受过化疗患者,MDACC研究纳入曾接受过治疗或新诊断患者。2个研究中的患者均未接受过免疫治疗。在PEMBRO-RT研究中患者被等比例随机分配入组,并根据吸烟状态进行分层(分为<10年组和≥10年组)。MDACC研究的患者根据放疗计划可行性被等比例随机分配入2个受试组。由于联合治疗组的干预本质,每个研究中的放疗均不适用盲法。在2个研究中,不论是否进行放疗,均静脉滴入帕博利珠单抗(每3周200 mg)。在PEMBRO-RT研究中,在放疗(24 Gy 3次分割照射)结束后1周给予第1剂帕博利珠单抗。在MDACC研究中,在第1次放疗(50 Gy 4次分割照射或45 Gy 15次分割照射)同时给予帕博利珠单抗。仅检测未经照射病灶的应答。本研究的终点为最佳射野外(远隔)应答率(ARR)、最佳射野外疾病控制率(ACR)、12周时ARR、12周时ACR、无进展生存期(PFS)和总生存期(OS)。2个研究的意向治疗(ITT)人群均纳入分析。PEMBRO-RT研究(NCT02492568)和MDACC研究(NCT02444741)均在ClinicalTrials.gov上注册。发现纳入148例患者,76例接受帕博利珠单抗治疗,72例接受帕博利珠单抗+放疗治疗。所有患者随访时间中位数为33个月[四分位距(IQR):32.4~33.6]。148例患者中124例(84%)组织学特征为非鳞癌,111例(75%)患者曾经接受过化疗。组间没有基线特征差异,包括PD-L1表达状态和转移灶体积。最常见的照射部位为肺转移灶(39%,28/72)、胸腔内淋巴结(21%,15/72)和非原发灶(17%,12/72)。帕博利珠单抗组和联合治疗组的最佳ARR分别为19.7%(15/76)和41.7%(30/72),OR=2.96,95%CI:1.42~6.20,P=0.0039;最佳ACR分别为43.4%(33/76)和65.3%(47/72),OR=2.51,95%CI:1.28~4.91,P=0.0071;PFS中位数分别为4.4(IQR:2.9~5.9)和9.0个月(IQR:6.8~11.2),HR=0.67,95%CI:0.45~0.99,P=0.045;OS中位数分别为8.7(IQR:6.4~11.0)和19.2个月(IQR:14.6~23.8),OR=0.67,95%CI:0.54~0.84,P=0.0004。在汇总分析中没有发现新的安全问题。解读帕博利珠单抗免疫疗法+放疗显著提高转移性NSCLC患者的应答和改善治疗结局。这些结果需要在三期临床试验中进行验证。 | 陈大卫(翻译) 于金明(校对) Willemijn S M E Theelen Vivek Verma Brian P Hobbs Heike M U Peulen Joachim G J V Aerts Idris Bahce Anna Larissa N Niemeijer Joe Y Chang Patricia M de Groot Quynh-Nhu Nguyen Nathan I Comeaux George R Simon Ferdinandos Skoulidis Steven H Lin Kewen He Roshal Patel John Heymach Paul Baas James W Welsh | 2021 | 中华肿瘤防治杂志2021，28，24： | 49 |
| 3 | Gut flora and bacterial translocation in chronic liver disease显示文摘增加的证据建议内脏植物群的精神错乱具有到有肝硬化的病人的实质的临床的关联。特别地,肠的细菌的增生和从肠的腔的内脏植物群的增加的细菌的易位在这个组为细菌的感染预先安排到一个增加的潜力。最近的研究建议除了他们在公开易传染的事件的致病和败血的临床的后果的角色,内脏植物群甚至当公开感染不在时贡献肝硬化的支持 inflammatory 状态。而且,内脏植物群的操作可以有利在肝脏硬化症的病人影响肝功能与更病原的潜力在损坏另外的内脏植物群种类的情况下扩充乳的酸类型的细菌的肠的内容。这里,我们在这个组考察在内脏植物群,细菌的易位,细菌的感染,支持 inflammatory cytokine 生产和肝功能之间的各种各样的相互关系的当前的概念。 | John Almeida Sumedha Galhenage Jennifer Yu Jelica Kurtovic Stephen M Riordan | 2006 | World Journal of Gastroenterology2006，12，10： | 37 |
| 4 | Functional dyspepsia:The role of visceral hypersensitivity in its pathogenesis显示文摘功能,或非溃疡,消化不良(FD ) 是为到胃的肠学的工作分派的最普通的原因之一。它与重要病态被联系并且损害了生命的质量。许多当局相信那机能性消化不良和急躁的肠症候群代表一样的疾病过程的光谱的部分。FD 的病理生理学仍然保持不清楚但是几个理论包括内脏的超敏性,胃的马达机能障碍, Helicobacter pylori 感染和精神分析被建议了社会因素。在这评论,迄今为止,我们在 FD 的原因论为内脏的超敏性的角色看证据。 | John Keohane Eamonn M M Quigley | 2006 | World Journal of Gastroenterology2006，12，17： | 35 |
| 5 | Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers显示文摘Gastric cancer and liver cancer are among the most common malignancies and the leading causes of death worldwide,due to late detection and high recurrence rates.Today,these cancers have a heavy socioeconomic burden,for which a full understanding of their pathophysiological features is warranted to search for promising biomarkers and therapeutic targets.Osteopontin (OPN) is overexpressed in most patients with gastric and liver cancers.Over the past decade,emerging evidence has revealed a correlation of OPN level and clinicopathological features and prognosis in gastric and liver cancers,indicating its potential as an independent prognostic indicator in such patients.Functional studies have verified the potential of OPN knockdown as a therapeutic approach in vitro and in vivo .Furthermore,OPN mediates multifaceted roles in the interaction between cancer cells and the tumor microenvironment,in which many details need further exploration.OPN signaling results in various functions,including prevention of apoptosis,modulation of angiogenesis,malfunction of tumor-associated macrophages,degradation of extracellular matrix,activation of phosphoinositide 3-kinase-Akt and nuclear factor-κB pathways,which lead to tumor formation and progression,particularly in gastric and liver cancers.This editorial aims to review recent findings on alteration in OPN expression and its clinicopathological associations with tumor progression,its potential as a therapeutic target,and putative mechanisms in gastric and liver cancers.Better understanding of the implications of OPN in tumorigenesis might facilitate development of therapeutic regimens to benefit patients with these deadly malignancies. | Dong-Xing Cao Zhi-Jie Li Xiao-Ou Jiang Yick Liang Lum Ester Khin Nikki P Lee Guo-Hao Wu John M Luk | 2012 | World Journal of Gastroenterology2012，18，30： | 29 |
| 6 | Ligation-assisted endoscopic mucosal resection of gastric heterotopic pancreas显示文摘Heterotopic pancreas is a congenital anomaly characterized by ectopic pancreatic tissue.Treatment of heterotopic pancreas may include expectant observation,endoscopic resection or surgery.The aim of this report was to describe the technique of ligation-assisted endoscopic mucosal resection(EMR) for resection of heterotopic pancreas of the stomach.Two patients(both female,mean age 32 years) were referred for management of gastric subepithelial tumors.Endoscopic ultrasound in both disclosed small hypoechoic masses in the mucosa and submucosa.Band ligation-assisted EMR was performed in both cases without complications.Pathology from the resected tumors revealed heterotopic pancreas arising from the submucosa.Margins were free of pancreatic tissue.Ligation-assisted EMR is technically feasible and may be considered for the endoscopic management of heterotopic pancreas. | Mouen A Khashab Oscar W Cummings John M DeWitt | 2009 | World Journal of Gastroenterology2009，15，22： | 25 |
| 7 | 甘草次酸靶向肝星状细胞治疗肝纤维化的体内研究显示文摘目的观察以6-磷酸甘露糖修饰的白蛋白(M6P26-HSA)作为特异性载体,将甘草次酸(GA) 靶向释放到肝星状细胞治疗肝纤维化的效果。方法用125I记由M6P26-HSA和GA在体外合成新的偶合物GA-HSA-M6P26,观察其在体内的器官分布情况,用双重免疫组织化学的方法观察星状细胞对GA- HSA-M6P26的选择性摄取;选用Sirius红染色观察GA-HSA-M6P26对肝纤维化时胶原沉积的影响,用定量聚合酶链反应检测GA-HSA-M6P26对Ⅰ型前胶原mRNA表达的影响。结果静脉注射后10min,GA-HSA- M6P26选择性地分布于肝脏,摄取高峰可达(5 5.093±5.404)%。双重免疫组织化学染色证实GA-HSA- M6P26主要被星状细胞选择性摄取,GA-HSA-M6P26治疗后肝脏胶原沉积明显减少,Ⅰ型前胶原和α-平滑肌肌动蛋白mRNA表达明显降低。结论GA-HSA-M6P26可以选择性地分布于肝脏星状细胞,有显著的抗肝纤维化作用。 | 张其胜 John M Luk 张健 田庚元 | 2005 | 中华肝脏病杂志2005，13，9： | 22 |
| 8 | Current status of laparoscopic and robotic ventral mesh rectopexy for external and internal rectal prolapse显示文摘External and internal rectal prolapse with their affiliated rectocele and enterocele, are associated with debilitating symptoms such as obstructed defecation, pelvic pain and faecal incontinence. Since perineal procedures are associated with a higher recurrence rate, an abdominal approach is commonly preferred. Despite the description of greater than three hundred different procedures, thus far no clear superiority of one surgical technique has been demonstrated. Ventral mesh rectopexy(VMR) is a relatively new and promising technique to correct rectal prolapse. In contrast to the abdominal procedures of past decades, VMR avoids posterolateral rectal mobilisation and thereby minimizes the risk of postoperative constipation. Because of a perceived acceptable recurrence rate, good functional results and low mesh-related morbidity in the short to medium term, VMR has been popularized in the past decade. Laparoscopic or robotic-assisted VMR is now being progressively performed internationally and several articles and guidelines propose the procedure as the treatment of choice for rectal prolapse. In this article, an outline of the current status of laparoscopic and robotic ventral mesh rectopexy for the treatment of internal and external rectal prolapse is presented. | Jan J van Iersel Tim JC Paulides Paul M Verheijen John W Lumley Ivo AMJ Broeders Esther CJ Consten | 2016 | World Journal of Gastroenterology2016，22，21： | 20 |
| 9 | Sharing Clinical Trial Data: A Proposal from the International Committee of Medical Journal Editors显示文摘The International Committee of Medical Journal Editors (ICMJE) believes that there is an ethical obligation to responsibly share data generated by interventional clinical trials because participants have put themselves at risk.In a growing consensus,many funders around the world-foundations,government agencies,and industry-now mandate data sharing.Here,we outline ICMJE's proposed requirements to help meet this obligation.We encourage feedback on the proposed requirements.Anyone can provide feedback at www.icmje.org by April 18,2016. | Darren B Taichman Joyce Backus Christopher Baethge Howard Bauchner Peter W de Leeuw Jeffrey M Drazen John Fletcher Frank Frizelle Irish Groves Abraham Haileamlak Astrid James Christine Laine Larry Peiperl Anja Pinborg Peush Sahni Si-Nan Wu | 2016 | Chinese Medical Journal2016，，2： | 20 |
| 10 | Role of LPS/CD14/TLR4-mediated inflammation in necrotizing enterocolitis:Pathogenesis and therapeutic implications显示文摘AIM:To establish the roles of lipopolysaccharide (LPS)/CD14/toll-like receptor 4 (TLR4)-mediated inflammation in a rat model of human necrotizing enterocolitis (NEC).METHODS: Six pairs of intestinal samples from human NEC were collected before and after recovery for histological and molecular analysis of inflammatory cytokines and signaling components. In the rat NEC model, we isolated 10-cm jejunum segments and divided them into six groups (n=6) for sham operation, treatment with LPS, bowel distension, combined bowel distension and LPS stimulation, and two therapeutic groups. The potential eff icacy of a recombinant CD18 peptide and a monoclonal CD14 antibody was evaluated in the latter two groups. The serum and tissue levels of several inflammatory mediators were quantified by real-time polymerase chain reaction, ELISA and immunoblotting.RESULTS: Human acute phase NEC tissues displayed significant increases (P<0.05) in levels of TLR4, CD14, myeloid differentiation protein (MD)-2, tumor necrosis factor (TNF)-α and nuclear factor-κB when compared to those after recovery. The histological and inflammatory picture of human NEC was reproduced in rats that were treated with combined bowel distension and LPS, but not in the sham-operated and other control rats. Serum levels of interleukin-6 and TNF-α were also elevated. The NEC pathology was attenuated by treating the NEC rats with a monoclonal CD14 antibody or an LPS-neutralizing peptide.CONCLUSION:LPS and distension are required to produce the histological and inflammatory features of NEC. A potential treatment option is blocking LPS activation and leukocyte infi ltration. | Kwong L Chan Kwong F Wong John M Luk | 2009 | World Journal of Gastroenterology2009，15，38： | 17 |
| 11 | Visceral hypersensitivity and electromechanical dysfunction as therapeutic targets in pediatric functional dyspepsia显示文摘Functional gastrointestinal disorders(FGID) are common clinical syndromes diagnosed in the absence of biochemical,structural,or metabolic abnormalities. They account for significant morbidity and health care expenditures and are identifiable across variable age,geography,and culture. Etiology of abdominal pain associated FGIDs,including functional dyspepsia(FD),remains incompletely understood,but growing evidence implicates the importance of visceral hypersensitivity and electromechanical dysfunction. This manuscript explores data supporting the role of visceral hypersensitivity and electromechanical dysfunction in FD,with focus on pediatric data when available,and provides a summary of potential therapeutic targets. | John M Rosen Jose T Cocjin Jennifer V Schurman Jennifer M Colombo Craig A Friesen | 2014 | World Journal of Gastrointestinal Pharmacology and Therapeutics2014，5，3： | 16 |
| 12 | 草莓的化学成分研究显示文摘目的 :对草莓的化学成分进行研究。方法 :色谱法分离化合物 ,波谱和化学法进行结构鉴定。结果 :从果实中分离得到 3个化合物 ,鉴定为环阿廷醇 ,14 甲基 豆甾 7,2 4(2 8)二烯 3β 醇和 β 谷甾醇。 结论 :3个化合物均为首次从该植物中获得。 | 阮金兰 陈静波 赵晓亚 孙南君 John M Cassady Gary D Stoner | 2001 | 中国中药杂志2001，26，9： | 16 |
| 13 | Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study显示文摘 | Patrick Marcellin Edward Gane Maria Buti Nezam Afdhal William Sievert Ira M Jacobson Mary Kay Washington George Germanidis John F Flaherty Raul Aguilar Schall Jeffrey D Bornstein Kathryn M Kitrinos G Mani Subramanian John G McHutchison E Jenny Heathcote | 2012 | The Lancet2012，，： | 14 |
| 14 | Beyond the Pediatric end-stage liver disease system: Solutions for infants with biliary atresia requiring liver transplant显示文摘Biliary atresia(BA), a chronic progressive cholestatic disease of infants, is the leading cause for liver transplant in children, especially in patients under two years of age. BA can be successfully treated with the Kasai portoenterostomy; however most patients still require a liver transplant, with up to one half of BA children needing a transplant by age two. In the current pediatric end-stage liver disease system, children with BA face the risk of not receiving a liver in a safe and timely manner. In this review, we discuss a number of possible solutions to help these children. We focus on two general approaches:(1) preventing/delaying need for transplantation, by optimizing the success of the Kasai operation; and(2) expediting transplantation when needed, by performing techniques other than the standard deceased-donor, whole, ABO-matched organ transplant. | Mary Elizabeth M Tessier Sanjiv Harpavat Ross W Shepherd Girish S Hiremath Mary L Brandt Amy Fisher John A Goss | 2014 | World Journal of Gastroenterology2014，20，32： | 14 |
| 15 | Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett's esophagus to adenocarcinoma显示文摘瞄准:在整个 Barretts 食管的前进调查 cyclooxygenase-2 (COX-2 ) 和上皮的生长因素受体(EGFR ) 的表示() 。方法:COX-2 和 EGFR 蛋白质表情被使用免疫检测组织化学的方法。详细 cytomorphological 改变的 A 是坚定的。COX-2 和 EGFR 表示的区域被使用计算机成像系统确定。结果:COX-2 和 EGFR 的表情与前进一起增加了从到食管腺癌(EAC ) 。积极关联在 COX-2 表示和 EGFR 表示之间被发现。结论:COX-2 和 EGFR 可能在逐步的前进从是合作的到 EAC,从而导致致癌作用。 | Yan Li John M Wo Mukunda B Ray Whitney Jones Ruifeng R Su Susan Ellis Robert C G Martin | 2006 | World Journal of Gastroenterology2006，12，6： | 14 |
| 16 | Surgery for inflammatory bowel disease显示文摘Despite the new and ever expanding array of medications for the treatment of inflammatory bowel disease (IBD), there are still clear indications for operative management of IBD and its complications. We present an overview of indications, procedures, considerations, and controversies in the surgical therapy of IBD. | John M Hwang Madhulika G Varma | 2008 | World Journal of Gastroenterology2008，14，17： | 13 |
| 17 | Severe scrub typhus infection: Clinical features, diagnostic challenges and management显示文摘Scrub typhus infection is an important cause of acute undifferentiated fever in South East Asia. The clinical picture is characterized by sudden onset fever with chills and non-specific symptoms that include headache, myalgia, sweating and vomiting. The presence of an eschar, in about half the patients with proven scrub typhus infection and usually seen in the axilla, groin or inguinal region, is characteristic of scrub typhus. Common laboratory findings are elevated liver transaminases, thrombocytopenia and leukocytosis. About a third of patients admitted to hospital with scrub typhus infection have evidence of organ dysfunction that may include respiratory failure, circulatory shock, mild renal or hepatic dysfunction, central nervous system involvement or hematological abnormalities. Since the symptoms and signs are non-specific and resemble other tropical infections like malaria, enteric fever, dengue or leptospirosis, appropriate laboratory tests are necessary to confirm diagnosis. Serological assays are the mainstay of diagnosis as they are easy to perform; the reference test is the indirect immunofluorescence assay(IFA) for the detection of Ig M antibodies. However in clinical practice, the enzyme-linked immuno-sorbent assay is done due to the ease of performing this test and a good sensitivity and sensitivity when compared with the IFA. Paired samples, obtained at least two weeks apart, demonstrating a ≥ 4 fold rise in titre, is necessary for confirmation of serologic diagnosis. The mainstay of treatment is the tetracycline group of antibiotics or chloramphenicol although macrolides are used alternatively. In mild cases, recovery is complete. In severe cases with multi-organ failure, mortality may be as high as 24%. | John Victor Peter Thomas I Sudarsan John Anthony J Prakash George M Varghese | 2015 | World Journal of Critical Care Medicine2015，4，3： | 13 |
| 18 | China Patient-centered Evaluative Assessment of Cardiac Events Prospective Study of Acute Myocardial Infarction: Study Design显示文摘 | Rachel P Dreyer Xi Li Xue Du Nicholas S Downing Li Li Hai-Bo Zhang Fang Feng Wen-Chi Guan Xiao Xu Shu-Xia Li Zhen-Qiu Lin Frederick A Masoudi John A Spertus Harlan M Krumholz Li-Xin Jiang | 2016 | Chinese Medical Journal2016，，1： | 13 |
| 19 | Liver iron transport显示文摘肝在铁新陈代谢起一个中央作用。它是为铁的主要存储地点并且也表示涉及铁运输和铁动态平衡的规定的分子的一个复杂范围。与肝的铁运输或规定联系的越来越多的基因被识别了。这些包括转铁蛋白受体(TFR1 并且 2 ) , ferrireductase (STEAP3 ) ,运输 ers 二价的金属 transporter-1 (DMT1 ) 和象 haemochromatosis 蛋白质, HFE 和 haemojuvelin (HJV ) 一样的 ferroportin (FPN ) ,它正在表明分子。许多也这些基因参予铁集中于肝的肽 hepcidin 的规章的小径。然而,我们开始仍然仅仅正在理解在肝之间的复杂相互作用熨运输和铁动态平衡。这评论在铁运输和铁动态平衡的规定构画出我们铁新陈代谢和他们的角色的分子的当前的知识。 | Ross M Graham Anita CG Chua Carly E Herbison John K Olynyk Debbie Trinder | 2007 | World Journal of Gastroenterology2007，13，35： | 12 |
| 20 | Dickkopfs and Wnt/β-catenin signalling in liver cancer显示文摘Liver cancer is the fifth and seventh most common cause of cancer in men and women,respectively.Wnt/β-catenin signalling has emerged as a critical player in both the development of normal liver as well as an oncogenic driver in hepatocellular carcinoma(HCC).Based on the current understanding,this article summarizes the possible mechanisms for the aberrant activation of this pathway with specific focus on HCC.Furthermore,we will discuss the role of dickkopfs(DKKs)in regulating Wnt/β-catenin signalling,which is poorly understood and understudied.DKKs are a family of secreted proteins that comprise at least four members,namely DKK1-DKK4,which act as inhibitors of Wnt/β-catenin signalling.Nevertheless,not all members antagonize Wnt/β-catenin signalling.Their functional significance in hepatocarcinogenesis remains to be further characterized for which these studies should provide new insights into the regulatory role of DKKs in Wnt/β-catenin signalling in hepatic carcinogenesis.Because of the important oncogenic roles,there are an increasing number of therapeutic molecules targetingβ-catenin and the Wnt/β-catenin pathway for potential therapy of HCC. | Sarwat Fatima Nikki P Lee John M Luk | 2011 | World Journal of Clinical Oncology2011，2，8： | 11 |
您所在的机构暂未开通此部分的功能，请联系管理员